#United States #New York #Class Action #Levi Korsinsky #Vistagen

Vistagen Therapeutics Faces Class Action Lawsuit

Legal troubles loom over Vistagen Therapeutics, Inc. (NASDAQ: VTGN) as news unfolds about a class action lawsuit filed by Levi & Korsinsky, LLP on behalf of investors affected by alleged securities fraud. This lawsuit is focused on incidents that occurred between April 1, 2024, and December 16, 2025, and seeks to recover losses incurred during this period.

Background of the Case

The concern arises from Vistagen’s handling of information relating to its Phase 3 PALISADE-3 trial for fasedienol, a drug intended for the treatment of social anxiety disorder. According to the complaint, the company made several promising statements regarding the drug's potential but simultaneously obscured critical details about the trial's outcomes. On December 17, 2025, Vistagen reported that the study did not meet its primary endpoint, leading to a sharp decline in its stock price from $4.36 to $0.86, indicating a staggering 80% drop. This drastic change has prompted investors to question the integrity of the information they were provided.

Class Action Details

The lawsuit claims that the misleading statements and omissions violated securities laws, consequently harming shareholders who invested during the specified interval. Investors who experienced losses are urged to come forward and join the suit. Notably, the deadline for participation is set for March 16, 2026, allowing investors a limited window to get involved. There is no financial cost associated with joining the class action—if one qualifies as a class member, they may receive compensation without any upfront fees or obligations.

What Actions Can Be Taken?

Investors who suffered losses are urged to reach out to Levi & Korsinsky, where they can discuss the details of their situation with a qualified attorney, Joseph E. Levi. There is potential for individuals to assume the role of lead plaintiff, although it is not a requirement for participation in any financial recovery.

For more information, investors can visit the firm’s dedicated webpage with details about the lawsuit or contact them directly through email or phone:

• - Email: [email protected]
• - Phone: (212) 363-7500

The Track Record of Levi & Korsinsky

Levi & Korsinsky is a well-established legal firm with a robust history of advocating for investors. Over the past two decades, they have secured hundreds of millions of dollars for their clients in cases involving securities litigation, making them one of the top-rated firms in the field according to the ISS Securities Class Action Services. Their team of over 70 professionals is dedicated to helping investors navigate complex legal challenges with the aim of delivering favorable outcomes.

Conclusion

As Vistagen navigates through this turbulent period, investors should remain vigilant and consider their legal options. The class action lawsuit not only seeks restitution for affected investors but also underscores the importance of corporate accountability in the pharmaceutical sector. Interested parties must act before the March 16 deadline to ensure their voices are heard and rights are protected. With a seasoned law firm like Levi & Korsinsky at the helm, there is hope for securing restitution for those impacted by this unfolding situation.